Medicare Enrolled

Dr. Jim Kim, MD

Rheumatology · Bakersfield, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
2203 17TH ST, Bakersfield, CA 93301
6617160333
In practice since 2006 (19 years)
NPI: 1992762769 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kim from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kim? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kim

Dr. Jim Kim is a rheumatology specialist in Bakersfield, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kim performed 161,224 Medicare services across 1,946 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kim received a total of $18,528 from 40 pharmaceutical and/or device companies across 844 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kim is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 3% volume in CA $18,528 industry payments

Medicare Practice Summary

Medicare Utilization ↗
161,224
Medicare services
Top 3% in CA for rheumatology
1,946
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,485 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Tocilizumab injection (Actemra) 89,800 $5 $10
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
28,150 $34 $70
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
15,700 $11 $45
Denosumab injection (Prolia/Xgeva) 9,900 $17 $28
Inclisiran injection (Leqvio) for cholesterol 9,088 $9 $25
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
3,760 $26 $150
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
879 $69 $100
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
813 $66 $125
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
751 $1 $20
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
494 $55 $270
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
444 $97 $175
Methylprednisolone injection, up to 40 mg
An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg.
286 $3 $15
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
259 $113 $270
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
253 $12 $50
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
204 $13 $50
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
167 $81 $150
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
125 $6 $25
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
100 $24 $80
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
51 $8 $20
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.5% high complexity
68.1% medium
1.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$18,528
Total received (2018-2024)
Avg $2,647/year across 7 years
Top 19% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
844
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,528 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,385
2023
$2,043
2022
$3,823
2021
$2,194
2020
$2,425
2019
$2,732
2018
$1,926

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$977
Janssen Biotech, Inc.
$393
AstraZeneca Pharmaceuticals LP
$278
ABBVIE INC.
$195
US Oncology Corporate, Inc.
$192
Fresenius Kabi USA, LLC
$182
Aurinia Pharma U.S., Inc.
$148
Boehringer Ingelheim Pharmaceuticals, Inc.
$135
PFIZER INC.
$132
UCB, Inc.
$126
E.R. Squibb & Sons, L.L.C.
$106
Novartis Pharmaceuticals Corporation
$99
GlaxoSmithKline, LLC.
$98
Organon Llc
$81
Mallinckrodt Hospital Products Inc.
$46
SCILEX PHARMACEUTICALS INC.
$40
Genentech USA, Inc.
$31
Octapharma USA, Inc.
$30
Ultragenyx Pharmaceutical Inc.
$22
SHORLA ONCOLOGY INC.
$21
Alvogen Inc
$21
Alexion Pharmaceuticals, Inc.
$18
Kiniksa Pharmaceuticals International, plc
$18
Top 3 companies account for 48.7% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$5,810
Janssen Biotech, Inc.
$1,547
Intuitive Surgical, Inc.
$1,071
E.R. Squibb & Sons, L.L.C.
$1,025
GlaxoSmithKline, LLC.
$923
Novartis Pharmaceuticals Corporation
$900
ABBVIE INC.
$845
AstraZeneca Pharmaceuticals LP
$759
Genentech USA, Inc.
$706
PFIZER INC.
$684
AbbVie Inc.
$625
AbbVie, Inc.
$502
Celgene Corporation
$488
UCB, Inc.
$296
Aurinia Pharma U.S., Inc.
$283
Horizon Therapeutics plc
$223
Fresenius Kabi USA, LLC
$209
US Oncology Corporate, Inc.
$192
Janssen Scientific Affairs, LLC
$192
Lilly USA, LLC
$186
Radius Health, Inc.
$156
Boehringer Ingelheim Pharmaceuticals, Inc.
$153
Alexion Pharmaceuticals, Inc.
$91
GENZYME CORPORATION
$83
Organon Llc
$81
Stryker Corporation
$63
Allergan Inc.
$62
ANI Pharmaceuticals, Inc.
$48
Organon LLC
$47
Mallinckrodt Hospital Products Inc.
$46
SCILEX PHARMACEUTICALS INC.
$40
Octapharma USA, Inc.
$30
Bio Products Laboratory USA, Inc.
$26
Ultragenyx Pharmaceutical Inc.
$22
SHORLA ONCOLOGY INC.
$21
Alvogen Inc
$21
Sobi, Inc
$20
Exeltis, USA Inc.
$19
Kiniksa Pharmaceuticals, Ltd.
$18
Kiniksa Pharmaceuticals International, plc
$18
Top 3 companies account for 45.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · Arcalyst · BENLYSTA · BYSTOLIC · Bimzelx · CACTUS · COSENTYX · CYLTEZO · Cimzia · Crysvita · Da Vinci Surgical System · EVENITY · Enbrel · Gammaplex · HADLIMA · HUMIRA · Humira · IDACIO · ILARIS · INFLECTRA · JYLAMVO · KEVZARA · KINERET · KRYSTEXXA · LUPKYNIS · LYRICA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SURG - NEPTUNE · SURG - SURGICAL SAFETY-SURGICOUNT · Strensiq · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tymlos · UBRELVY · UPLIZNA · VRAYLAR · XELJANZ · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Bakersfield?
Compare rheumatologists in the Bakersfield area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
5
Per 100K population
0.5
County median income
$67,660
Nearest hospital
BAKERSFIELD MEMORIAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Kim is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with low-engagement industry engagement in the top 19% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Kim experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Kim performed 89,800 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kim receive payments from pharmaceutical companies?
Yes. Dr. Kim received a total of $18,528 from 40 companies across 844 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kim's costs compare to other rheumatologists in Bakersfield?
Dr. Kim's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kim) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →